•  
No Bestinvest rating
Find rated global funds
LEGAL & GENERAL GLOBAL HEALTH & PHARMACEUTICAL INDEX R

LEGAL & GENERAL GLOBAL HEALTH & PHARMACEUTICAL INDEX R - Overview

Overview of LEGAL & GENERAL GLOBAL HEALTH & PHARMACEUTICAL INDEX R

The first trust to track global blue chip healthcare & pharmaceutical companies, it offers a passive option to technology investing with an emphasis on established giants. Our opinion however is that within emerging, specialist sectors, dedicated active managers add value and perform better.

  • Standard Initial Charge 0.00%
  • Initial charge via Bestinvest 0.00%

Fund summary

Sector Global
Structure UNIT TRUST
Launched November, 2000
Size £130m
Yield 0.7%
Charging basis Income
Dividends paid 7th March.

Charges

Standard initial charge 0.00%
Initial charge via Bestinvest 0.00%
Additional bid/offer spread 0.16%
Annual management charge 1.00%
Total expense ratio 1.00%

Risks

Before investing make sure you have understood the risks relevant to the fund by reviewing our Risk Warnings section. Further information on the risks are contained in the fund's Key Investor Information Document, which we make available to you before you make a decision to invest, alternatively it is available on request.

Bestinvest view

No information available.

Portfolio

Allocation Proportion(%)
Equity 100
High yield bonds 0
Quality bonds 0
Property 0
Commodities 0
Hedge 0
Fund cash 0
Allocation Proportion(%)
UK 10
Europe 18
North America 65
Japan 5
Pacific 1
Other Equity 1
Allocation Proportion(%)
Large Caps 88
Mid Caps 12
Small Caps 0

View all performance data for this fund

Investment process

The investment objective is to secure capital growth from a portfolio of securities of companies engaged in Health and Pharmaceuticals. Securities representing all such companies in the developed and advanced emerging segments of the FTSE All-World Index will normally be held with weighting generally proportionate to their market capitalisation. The largest 90% of companies by market cap are covered, which number around 90. Since Pfizer exceeds the 10% limit in any one stock imposed by IMRO, the trust will hold Medium Term Notes to simulate the performance of the shares. The fund fully replicates the index.

Live feed

Bid price(inc) (6.34p) 43.06p
Accum units 47.40p
Fund commentary
Fund data updated on 16/12/14

* This fund is part of our annual bonus scheme to which conditions apply. If you qualify for the bonus it will be paid on any holding of this fund that you have in your Investment, ISA or SIPP accounts.

Asset allocation

Allocation Proportion(%)
Equity 100
High yield bonds 0
Quality bonds 0
Property 0
Commodities 0
Hedge 0
Fund cash 0

Equity Geographic

Allocation Proportion(%)
UK 10
Europe 18
North America 65
Japan 5
Pacific 1
Other Equity 1

Equity Capitalisation

Allocation Propor
tion(%)
Large Caps 88
Mid Caps 12
Small Caps 0

Top 10 holdings

As at: 31/08/2014
7.45% Johnson & Johnson
5.48% Novartis Ag
5.37% Roche Hldg Ag
4.91% Pfizer Inc
4.53% Merck & Co Inc(New)
4.28% Gilead Sciences Inc
3.3% Sanofi
3.12% Glaxosmithkline
2.75% Amgen Inc
2.5% Astrazeneca Plc
Source: Trustnet

Sector breakdown

Health Care 99%
Cash & Cash Equivalents 1%

Portfolio details

No information available.

Constraints

No information available.

Average monthly relative returns Bestinvest MRI
09/10 10/11 11/12 12/13 13/14   3 years 5 years Career 3 years 5 years Career
0.39% 0.21% -0.21%   0.13% 0.19% 69.20% 77.90%
Performance figures are based on the average of monthly percentage returns relative to the benchmark index.

Joseph Molloy

Manager. Molloy joined LGIM’s index fund team in November 2009 and is responsible for the management of a number of international equity index portfolios. Previously, he was at Northern Trust Global Investors for three years, working as an index fund manager, specialising in Emerging Market portfolios for both pooled and segregated funds. He performed a similar role at State Street Global Advisors. Molloy started his investment management career with Gulf International Bank as a Portfolio Dealer. He is a member of both the FTSE Nationality Committee and the FTSE Americas Committee.

Track record

Joseph Molloy has 3.8 years experience of managing mutual funds in this sector. Over this period the average monthly return relative to the benchmark index has been +0.19%. During the worst period of relative performance (from April 2013 - June 2013) there was a decline of 6% relative to the index. The worst absolute loss has been 7%. Statistically, we estimate the probability that this fund manager is adding value, rather than being lucky, is 78%.

Periods of worst performance
Absolute -7% (June 2011 - September 2011)
Relative -6% (April 2013 - June 2013)

Sector record since February 2011 (4 yrs)




About the MRI

Our unique indicator: the Bestinvest Manager Record Index (MRI) measures the likelihood that the fund manager is adding value through their decisions. It is based on their performance record over the course of their career, adjusted for the amount of risk taken. MRI is an important contributor to our fund rating system but it is also vital to take account of qualitative factors. It is also very important to select funds to form a cohesive portfolio with an appropriate overall risk level.

Invest in an existing account

This fund is not available to invest

Open a new account

This fund is not available to invest